Clinical ink

We're #hiring a new Senior Mobile Software Engineer (React Native) in United States. Apply today or share this post with your network.

We're #hiring a new Manager, Data Management in United States. Apply today or share this post with your network.

We're #hiring a new Director, Data Management in United States. Apply today or share this post with your network.

We're #hiring a new Project Manager II in United States. Apply today or share this post with your network.

We’re #hiring a new RFI/RFP Manager in United States. Apply today or share this post with your network.

We’re #hiring a new Outcome Solutions Manager (EU-Based) in United States. Apply today or share this post with your network.

Clinical ink is pleased to announce our exclusive license of SPUR?, an AI-enabled patient engagement and retention tool for predicting clinical trial adherence.?SPUR was developed by Observia and is validated by extensive published literature and is currently used in over 40,000 patients across 27 therapeutic areas. Chief Medical Officer Nicholas Alp commented, “Not only does this validated tool help sponsors comply with FDA guidance on lifestyle standardization in certain therapeutic classes such as GLP-1, but it also offers unique insights to investigators, helping them support participant adherence to the protocol.?This predicts and reduces the risk of drop out, preserving study power.” Every participant who discontinues study drug, doesn’t follow the protocol, or drops out of a study reduces its statistical power and its credibility. SPUR is a unique adherence solution that offers a validated individual behavioural diagnosis and intervention plan for each participant. The research investigator receives a participant profile, predicting the risk of poor adherence, an analysis of the drivers of that risk, and personalized communication guidance to improve engagement and adherence. SPUR can be further enhanced with the d.tells? AI engine.?d.tells refines the personalization feedback to the participant by adapting the frequency, duration, and tone of the messages and notifications it sends, according to the patient's sociomedical and behavioral data. Read more in our press release: https://lnkd.in/ebQ2QUGw

So excited for my first networking event at Clinical ink! ? March 25th, 5:30-8:30 PM ?? The Ice Room at Javier's La Jolla ?? SoCal biotech leaders Always love hosting industry friends for cocktails at one of my favorite spots! Please stop by for any part of the evening to connect with our innovative San Diego biotech community. ?? Planning to attend? Drop me a message so we can get a headcount! ??

Calling all Southern California life sciences leaders:? Please join Clinical Ink on Tuesday, March 25th, at The Ice Room at Javier's, La Jolla. Whether you can drop by for a quick hello or plan to stay the entire evening, Clinical Ink would love to host you for an evening of cocktails and conversation amidst other local biotech leaders. ? ?? Location: The Ice Room at Javier's, La Jolla ??? Date: Tuesday, March 25th ? Time: 5:30 PM - 8:30 PM ? Looking forward to connecting with you!

Clinical ink is pleased to announce our exclusive license of SPUR?, an AI-enabled patient engagement and retention tool for predicting clinical trial adherence.?SPUR was developed by Observia and is validated by extensive published literature and is currently used in over 40,000 patients across 27 therapeutic areas. Chief Medical Officer Nicholas Alp commented, “Not only does this validated tool help sponsors comply with FDA guidance on lifestyle standardization in certain therapeutic classes such as GLP-1, but it also offers unique insights to investigators, helping them support participant adherence to the protocol.?This predicts and reduces the risk of drop out, preserving study power.” Every participant who discontinues study drug, doesn’t follow the protocol, or drops out of a study reduces its statistical power and its credibility. SPUR is a unique adherence solution that offers a validated individual behavioural diagnosis and intervention plan for each participant. The research investigator receives a participant profile, predicting the risk of poor adherence, an analysis of the drivers of that risk, and personalized communication guidance to improve engagement and adherence. SPUR can be further enhanced with the d.tells? AI engine.?d.tells refines the personalization feedback to the participant by adapting the frequency, duration, and tone of the messages and notifications it sends, according to the patient's sociomedical and behavioral data. Read more in our press release: https://lnkd.in/ebQ2QUGw